Global prevalence of young-onset dementia examined
Jul 20, 2021
Worldwide, an estimated 3.9 million people aged 30 to 64 years are living with young-onset dementia.
Mirtazapine does not reduce agitation in dementia patients
Nov 03, 2021
In a randomized, double-blind trial, no difference was seen in scores for agitated behaviors at 12 weeks with mirtazapine versus placebo.
Memory concerns stable, but incidence of cognitive decline increased
Mar 31, 2022
Women, those older than 80 years and those living in more deprived areas are more likely to have memory concern and cognitive decline recorded in primary care.
Risks for neurologic, psychiatric sequelae persist after COVID-19
Sep 02, 2022
Adults have increased risks for cognitive deficit, dementia, psychotic disorders, epilepsy or seizures at two-year follow-up.
Alzheimer’s disease, related dementia diagnoses up in Medicare decedents
Apr 01, 2022
The percentage of older U.S. decedents with a diagnosis of Alzheimer’s disease and related dementias increased significantly from 2004 to 2017.
Risk for decline up for low-income seniors after ICU stay
Mar 08, 2022
The risks for disability and transition to probable dementia increased after an ICU stay for seniors with dual eligibility for Medicare and Medicaid.
DMARDs not linked to Alzheimer’s risk for seniors with RA
Apr 12, 2022
No reduction in the risk for Alzheimer’s disease and related dementia was seen with treatment with tofacitinib, tocilizumab or tumor necrosis factor inhibitors versus abatacept.
Medicare policy changes tied to drop in hospice use for dementia
May 09, 2022
Immediate and lasting reductions were seen in the share of patients receiving hospice care with the Alzheimer’s disease and related dementia code.
App-based protocol ID’s delirium in hospitalized adults
Nov 08, 2021
Overall accuracy of two-step protocol including two-item screen and 3-minute diagnostic assessment was 89%, 87% for nurses, doctors.
Two-hour oral glucose tolerance test can predict future episodic memory decline
Sep 24, 2021
A higher value on an oral glucose tolerance test at baseline was linked to worse performance and greater decline in a word-list delayed recall test.